U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H5O7.Cr.6H2O
Molecular Weight 349.1875
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHROMIC CITRATE HEXAHYDRATE

SMILES

O.O.O.O.O.O.[Cr+3].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

InChI

InChIKey=INHSZNHCJAIFJF-UHFFFAOYSA-K
InChI=1S/C6H8O7.Cr.6H2O/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;;;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;6*1H2/q;+3;;;;;;/p-3

HIDE SMILES / InChI

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C6H5O7
Molecular Weight 189.0997
Charge -3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Cr
Molecular Weight 51.9961
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Chromium sulfate(III) hexahydrate or chromium sulphate, a trivalent compound of chromium that was investigated as a toxic compound. Experiments on rodent have shown chromium sulfate produced severe and widespread effects in the nasal cavity, larynx, lungs, and mediastinal lymph node. Effects were characterized by the accumulation of foreign material, infiltration of alveolar macrophages, septal cell hyperplasia, and granulomatous and chronic inflammation. Besides, chromium sulphate exerted a disadvantageous effect on the skeleton, as it decreases bone density and resistance.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
CHROMIUM

Approved Use

Chromium 4 mcg/mL (Chromic Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition. Administration helps to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.

Launch Date

2005
PubMed

PubMed

TitleDatePubMed
Cytokine induction in human epidermal keratinocytes exposed to contact irritants and its relation to chemical-induced inflammation in mouse skin.
1994 Jun
Silicate antibodies in women with silicone breast implants: development of an assay for detection of humoral immunity.
1996 Mar
Activation of MAPKs in human bronchial epithelial cells exposed to metals.
1998 Sep
Transcriptional activation and posttranscriptional modification of Cyp1a1 by arsenite, cadmium, and chromium.
2007 Aug
Immunosuppressive effect of subchronic exposure to a mixture of eight heavy metals, found as groundwater contaminants in different areas of India, through drinking water in male rats.
2007 Oct
Patents

Patents

Substance Class Chemical
Created
by admin
on Sat Dec 16 18:26:58 GMT 2023
Edited
by admin
on Sat Dec 16 18:26:58 GMT 2023
Record UNII
35D7E8S8CQ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHROMIC CITRATE HEXAHYDRATE
Common Name English
1,2,3-PROPANETRICARBOXYLIC ACID, 2-HYDROXY-, CHROMIUM(3+) SALT (1:1), HEXAHYDRATE
Systematic Name English
1,2,3-PROPANETRICARBOXYLIC ACID, 2-HYDROXY-, CHROMIUM(3+) SALT, HYDRATE (1:1:6)
Systematic Name English
Code System Code Type Description
FDA UNII
35D7E8S8CQ
Created by admin on Sat Dec 16 18:26:59 GMT 2023 , Edited by admin on Sat Dec 16 18:26:59 GMT 2023
PRIMARY
CAS
96030-95-4
Created by admin on Sat Dec 16 18:26:59 GMT 2023 , Edited by admin on Sat Dec 16 18:26:59 GMT 2023
PRIMARY
PUBCHEM
91799719
Created by admin on Sat Dec 16 18:26:59 GMT 2023 , Edited by admin on Sat Dec 16 18:26:59 GMT 2023
PRIMARY
Related Record Type Details
ANHYDROUS->SOLVATE
Related Record Type Details
ACTIVE MOIETY